share_log

中國生物製藥：自願公告 - 根據限制性股份獎勵計劃購買股份

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

Hong Kong Stock Exchange ·  Apr 17 05:09
Summary by Moomoo AI
中國生物製藥有限公司（「本公司」）於2024年4月17日根據2018年1月5日採納的限制性股份獎勵計劃，透過受託人從市場購買了5,000,000股股份，以信託方式持有，準備授予獲選參與者。該次購買股份佔已發行股份總數的約0.027%，每股平均代價為2.459港元，總代價約為12,295,050港元。董事會將繼續檢討及決定未來根據該計劃授予的股份數目及購買的股份數目。本公司董事會包括七位執行董事及五位獨立非執行董事。
中國生物製藥有限公司（「本公司」）於2024年4月17日根據2018年1月5日採納的限制性股份獎勵計劃，透過受託人從市場購買了5,000,000股股份，以信託方式持有，準備授予獲選參與者。該次購買股份佔已發行股份總數的約0.027%，每股平均代價為2.459港元，總代價約為12,295,050港元。董事會將繼續檢討及決定未來根據該計劃授予的股份數目及購買的股份數目。本公司董事會包括七位執行董事及五位獨立非執行董事。
China Biopharmaceuticals Limited (the “Company”) on April 17, 2024 pursuant to the Restrictive Share Award Scheme adopted on January 5, 2018, purchased 5,000,000 shares from the market through trustees, held in trust and prepared to be granted to selected participants. The share purchase represented approximately 0.027% of the total issued shares, with an average price of HK$2.459 per share and a total cost of approximately HK$12,295,050. The Board of Directors will continue to review and decide on the number of shares to be granted in the future under the Scheme and the number of shares to be purchased. The Company's Board of Directors consists of seven executive directors and five independent non-executive directors.
China Biopharmaceuticals Limited (the “Company”) on April 17, 2024 pursuant to the Restrictive Share Award Scheme adopted on January 5, 2018, purchased 5,000,000 shares from the market through trustees, held in trust and prepared to be granted to selected participants. The share purchase represented approximately 0.027% of the total issued shares, with an average price of HK$2.459 per share and a total cost of approximately HK$12,295,050. The Board of Directors will continue to review and decide on the number of shares to be granted in the future under the Scheme and the number of shares to be purchased. The Company's Board of Directors consists of seven executive directors and five independent non-executive directors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more